Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

NCT01624766 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Advanced Malignant Neoplasm
Metastatic Malignant Neoplasm
Recurrent Malignant Neoplasm
Refractory Malignant Neoplasm

Interventions

BIOLOGICAL: Anakinra
BIOLOGICAL: Denosumab
DRUG: Everolimus

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]